Chembio Diagnostics, Medford, NY, has received a $4 million order from Bio-Manguinhos, Rio de Janeiro, for the purchase of Chembio’s DPP Covid-19 IgM/IgG system, to support the needs of Brazil’s Ministry of Health.

The DPP Covid-19 IgM/IgG system is a single-use rapid point-of-care test for the detection and differentiation of IgM and IgG antibodies to covid-19 in whole blood collected via fingerstick, using Chembio’s handheld analyzer, which achieved a CE mark and approval from the Brazilian Health Regulatory Agency during 2019. The system is intended for use in clinical and point-of-care settings to aid in the diagnosis of SARS‑CoV-2 infection.

“We are pleased to deepen our relationship with Bio-Manguinhos to address the serological testing needs surrounding covid-19,” says Javan Esfandiari, Chembio’s executive vice president and chief science and technology officer. “Recent studies reiterate that both molecular and serological tests are needed to definitively confirm a virus carrier, and the strength of our DPP platform technology enabled our team to develop a high quality test for SARS‑CoV‑2 efficiently and rapidly. Our serology test will detect the presence of antibodies in blood, indicating that a person had an immune response to SARS-CoV-2, regardless of whether symptoms developed from infection or if the infection was asymptomatic.”

For more information, visit Chembio Diagnostics.